동향
동향 내용
Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials
분류 Clinical Trial, Guidance 조회 2475
발행년도 2015 등록일 2015-10-02
출처 FDA (바로가기)
The purpose of this guidance is to assist sponsors in prospectively assessing the occurrence of treatment-emergent suicidal ideation and behavior in clinical trials of drug and biological products.
 
(후략)

목록



[추천 메일 발송]
추천 메일 발송
받는 분 이메일 @
추천인
리스트 이전글과 다음글
이전글이전글 Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products Tomography (PET) Drugs
다음글다음글 PROPOSED TEST FOR THE SUPPLEMENTARY INFORMATION SECTION OF THE INTERNATIONAL PHARMACOPOEIA RADIOPHARMACEUTICALS: TESTING-ADDITIONAL GUIDANCE